Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Article Title: Applicability of the shorter 'Bangladesh regimen' in high MDR-TB settings.
PMID/MRN: 27816662
Publication Date: 2016-Nov-02
Abstract:
In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB), clinicians are facing increasing problems in designing effective regimens in severe cases. Recently a 9 to 12-month regimen (known as Bangladesh regimen) proved to be effective in treating MDR-TB cases. It included an initial phase of 4 to 6 months of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high dose isoniazid and ethambutol followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol. However, recent evidence in Europe and Latin America identified prevalences of resistance to the first-line drugs composing the regimen (ethambutol and pyrazinamide) exceeding 60%, and of prothionamide exceeding 50%. Furthermore, the resistance proportion of the 2 most important pillars of the regimen (quinolones and kanamycin) were higher than 40%. Overall, only 14 out of 348 adult patients (4.0%) were susceptible to all the drugs composing the regimen, being therefore potentially suitable for the 'shorter regimen'. A shorter, cheaper and well tolerated MDR-TB regimen is likely to impact the number of patients treated and improve adherence if prescribed to the right patients through the systematic use of rapid MTBDRsl testing.
Copyright © 2016. Published by Elsevier Ltd.